Completing data — refresh the page later to see the latest
856436-16-3CS(=O)(=O)O.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1ccc[nH]1ZUDPNBZMAJGYTE-UHFFFAOYSA-N856436-16-3DTXSID80648020Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
UsesJI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ~40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ~250 and ~500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia[1].
General DescriptionA cell-permeable, potent, and reversible inhibitor of Janus kinase 3 (JAK3) (IC50 = 27 nM). Reported to bind to the enzyme active site and prevent IL-2-induced phosphorylation of JAK3 and STAT5. Also reported to inhibit IL-2-induced cell proliferation (IC50 = 760 nM for murine CTLL cells and 250 nM for human T-cells). Shown to alleviate oxazolone-induced ear edema in mice with an efficacy comparable to Dexamethasone (Cat. No. 265005) and displays ~16-fold greater selectivity over JAK2.